|
1
|
Noureddin M, Yates KP, Vaughn IA,
Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed
B, Doo E, Kleiner DE, et al: Clinical and histological determinants
of nonalcoholic steatohepatitis and advanced fibrosis in elderly
patients. Hepatology. 58:1644–1654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Evans CD, Oien KA, MacSween RN and Mills
PR: Non-alcoholic steatohepatitis: A common cause of progressive
chronic liver injury? J Clin Pathol. 55:689–692. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA,
Feldstein AF and Zein NN: The incidence and risk factors of
hepatocellular carcinoma in patients with nonalcoholic
steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adams LA, Lymp JF, St Sauver J, Sanderson
SO, Lindor KD, Feldstein A and Angulo P: The natural history of
nonalcoholic fatty liver disease: A population-based cohort study.
Gastroenterology. 129:113–121. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dunn W, Xu R, Wingard DL, Rogers C, Angulo
P, Younossi ZM and Schwimmer JB: Suspected nonalcoholic fatty liver
disease and mortality risk in a population-based cohort study. AM J
Gastroenterol. 103:2263–2271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong VW, Wong GL, Tsang SW, Fan T, Chu WC,
Woo J, Chan AW, Choi PC, Chim AM, Lau JY, et al: High prevalence of
colorectal neoplasm in patients with non-alcoholic steatohepatitis.
Gut. 60:829–836. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gastaldelli A, Kozakova M, Højlund K,
Flyvbjerg A, Favuzzi A, Mitrakou A and Balkau B: Fatty liver is
associated with insulin resistance, risk of coronary heart disease
and early atherosclerosis in a large European population.
Hepatology. 49:1537–1544. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bilici A, Ozguroglu M, Mihmanli I, Turna H
and Adaletli I: A case-control study of non-alcoholic fatty liver
disease in breast cancer. Med Oncol. 24:367–371. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pagadala MR, Zein CO, Dasarathy S, Yerian
LM, Lopez R and McCullough AJ: Prevalence of hypothyroidism in
nonalcoholic fatty liver disease. Dig Dis Sci. 57:528–534. 2012.
View Article : Google Scholar
|
|
10
|
Caballería L, Auladell MA, Torán P,
Miranda D, Aznar J, Pera G, Gil D, Muñoz L, Planas J, Canut S, et
al: Prevalence and factors associated with the presence of non
alcoholic fatty liver disease in an apparently healthy adult
population in primary care units. BMC Gastroenterol. 7:412007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gelpi Méndez JA, Castellanos Fillot A,
Sainz Gutiérrez JC, Quevedo Aguado L and Martin Barallat J:
Prevalence of non-alcoholic fatty liver disease and associated risk
factors among managers from the community of Madrid. Arch Prev
Riesgos Labor. 17:84–90. 2014.In Spanish. View Article : Google Scholar
|
|
12
|
Leite NC, Salles GF, Araujo AL,
Villela-Nogueira CA and Cardoso CR: Prevalence and associated
factors of non-alcoholic fatty liver disease in patients with
type-2 diabetes mellitus. Liver Int. 29:113–119. 2009. View Article : Google Scholar
|
|
13
|
Loria P, Lonardo A, Lombardini S, Carulli
L, Verrone A, Ganazzi D, Rudilosso A, D'Amico R, Bertolotti M and
Carulli N: Gallstone disease in non-alcoholic fatty liver:
Prevalence and associated factors. J Gastroen Hepatol.
20:1176–1184. 2005. View Article : Google Scholar
|
|
14
|
Radu C, Grigorescu M, Crisan D, Lupsor M,
Constantin D and Dina L: Prevalence and associated risk factors of
non-alcoholic fatty liver disease in hospitalized patients. J
Gastrointestin Liver Dis. 17:255–260. 2008.PubMed/NCBI
|
|
15
|
Hu KC, Wang HY, Liu SC, Liu CC, Hung CL,
Bair MJ, Liu CJ, Wu MS and Shih SC: Nonalcoholic fatty liver
disease: Updates in noninvasive diagnosis and correlation with
cardiovascular disease. World J Gastroenterol. 20:7718–7729. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanyal AJ: NASH: A global health problem.
Hepatol Res. 41:670–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takaki A, Kawai D and Yamamoto K:
Molecular mechanisms and new treatment strategies for non-alcoholic
steatohepatitis (NASH). Int J Mol Sci. 15:7352–7379. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Musso G, Anty R and Petta S: Antioxidant
therapy and drugs interfering with lipid metabolism: could they be
effective in NAFLD patients? Curr Pharm Des. 19:5297–5313. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yalcin M, Akarsu M, Celik A, Sagol O,
Tunali S, Ertener O, Bengi G and Akpinar H: A comparison of the
effects of infliximab, adalimumab, and pentoxifylline on rats with
non-alcoholic steatohepatitis. Turk J Gastroenterol. 25:167–175.
2014. View Article : Google Scholar
|
|
20
|
Fock KM and Khoo J: Diet and exercise in
management of obesity and overweight. J Gastroenterol Hepatol.
28:59–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beaton MD: Current treatment options for
nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Can J Gastroenterol. 26:353–357. 2012.PubMed/NCBI
|
|
22
|
Malaguarnera M, Di Rosa M, Nicoletti F and
Malaguarnera L: Molecular mechanisms involved in NAFLD progression.
J Mol Med (Berl). 87:679–695. 2009. View Article : Google Scholar
|
|
23
|
Satapathy SK, Garg S, Chauhan R, Sakhuja
P, Malhotra V, Sharma BC and Sarin SK: Beneficial effects of tumor
necrosis factor-alpha inhibition by pentoxifylline on clinical,
biochemical and metabolic parameters of patients with nonalcoholic
steatohepatitis. AM J Gastroenterol. 99:1946–1952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mitchel EB and Lavine JE: Review article:
the management of paediatric nonalcoholic fatty liver disease.
Aliment Pharmacol Ther. 40:1155–1170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Filippini P, Cesario A, Fini M, Locatelli
F and Rutella S: The Yin and Yang of non-neuronal α7 -nicotinic
receptors in inflammation and autoimmunity. Curr drug targets.
13:644–655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boeckxstaens G: The clinical importance of
the anti-inflammatory vagovagal reflex. Handb Clin Neurol.
117:119–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ganz M and Szabo G: Immune and
inflammatory pathways in NASH. Hepatol int. 7:771–781. 2013.
View Article : Google Scholar
|
|
28
|
Meli R, Mattace Raso G and Calignano A:
Role of innate immune response in non-alcoholic Fatty liver
disease: metabolic complications and therapeutic tools. Front
Immunol. 5:1772014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Braunersreuther V, Viviani GL, Mach F and
Montecucco F: Role of cytokines and chemokines in non-alcoholic
fatty liver disease. World J Gastroenterol. 18:727–735. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weiß J, Rau M and Geier A: Non-alcoholic
fatty liver disease epidemiology, clinical course, investigation,
and treatment. Dtsch Arztebl Int. 111:447–452. 2014.
|
|
31
|
Ratziu V, Goodman Z and Sanyal A: Current
efforts and trends in the treatment of NASH. J Hepatol. 62:S65–S75.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gadd VL, Skoien R, Powell EE, Fagan KJ,
Winterford C, Horsfall L, Irvine K and Clouston AD: The portal
inflammatory infiltrate and ductular reaction in human nonalcoholic
fatty liver. Hepatology. 59:1393–1405. 2014. View Article : Google Scholar
|
